Comparative Pharmacology
Head-to-head clinical analysis: HYDROPRES 25 versus HYDROPRES 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPRES 25 versus HYDROPRES 50.
HYDROPRES 25 vs HYDROPRES 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine uptake, leading to decreased sympathetic outflow.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine is a rauwolfia alkaloid that depletes catecholamines and serotonin from central and peripheral nerve endings, reducing sympathetic outflow and lowering blood pressure. The combination provides additive antihypertensive effect.
1 tablet orally once daily, each tablet contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Dosage may be increased to 2 tablets daily if needed.
HYDROPRES 50 is a fixed-dose combination of hydrochlorothiazide 50 mg and reserpine 0.125 mg. Usual adult dose: one tablet orally once daily.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hr; reserpine: 50-100 hr (terminal, with prolonged adrenergic depletion lasting days)
Hydrochlorothiazide: 6-15 hr (terminal); Reserpine: 50-100 hr (terminal, biphasic). Clinical: HCTZ half-life prolonged in renal impairment; reserpine accumulates with repetitive dosing.
Renal: hydrochlorothiazide 70% unchanged, reserpine ~30% unchanged; fecal: reserpine ~60% metabolites
Hydrochlorothiazide: 95% renal (65% unchanged); Reserpine: 30% renal, 60% fecal
Category C
Category C
Thiazide Diuretic Combination
Thiazide Diuretic Combination